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Bmi-1 was first found in Netherlands Cancer Center 
in 1991 and it belongs to the polycomb group gene fam-
ily (PcG) [1]. Bmi-1 overexpression has been indicated 
in several malignant diseases such as leukemia [2], lym-
phoma [3], colon carcinoma, small cell lung cancer and 
breast cancer [4, 5]. More recently, it has been shown 
that Bmi-1 is strongly expressed in primary neuroblasto-
mas [6, 7]. Since the identification of telomerase in 1985 
by Greider and Blackburn [8], the biological functions of 
telomerase have been extensively studied. Telomerase 
activation is directly correlated with cell immortalization 
and tumorigenesis and more than 85% of malignant 
tumor tissues were found to have enhanced telomerase 
expression [9]. Bmi-1 protein has been suggested to be 
closely related to the telomerase activity [10].
Currently, the expression of Bmi-1 in ovarian can-
cer tissues has not been reported. In this study, the 
correlation of Bmi-1 expression, telomerase activity 
and effects of Bmi-1 on genesis and development of 
ovarian epithelial cancer were investigated.
MATERIALS AND METHODS
Patient samples. 47 patients’ samples were randomly 
selected from the ovarian epithelial cancer cases admitted 
into the Department of Gynecology, Affiliated Oncology 
Hospital of Harbin Medical University from August 2006 to 
June 2007. All cases were confirmed as ovarian epithelial 
cancer by pathological examination. Ten cases of normal 
ovarian tissues were chosen as controls. Within 30 min 
after specimens were excised, portions of tissue were 
frozen at –70 oC. The rest were fixed using 10% formalin 
and embedded in paraffin. Of the 47 cancer cases, the age 
of the patients ranged from 30 to 72 y/o. Serous papillary 
adenocarcinoma was diagnosed in 28 cases, while the rest 
19 cases had mucoid adenocarcinoma. According to the 
staging method of International Federation of Gynecology 
and Obstetrics (FIGO), 9 cases had cancer of phase II, 
12 cases phase III and 26 cases phase IV.
Reagents. Mouse anti-human Bmi-1 monoclonal 
antibody was purchased from Upstate Company (USA). 
SP immunohistochemistry kit and antibody diluent were 
obtained from Beijing Zhongshan Company (China). 
Primers for Bim-1 were the same as reported by Kim 
et al [4] and they were as following: Forward: 5’-AATCC-
GTCGAGCAGAGTT-3’ and Reverse: 5’-CCCTTACCCT-
TACCCTTACCCTTAA-3’. Primers were synthesized by 
Shanghai Bioengineering Company (China).
SP immunohistochemical examination. Serial 
sections of 4 μm were taken from each paraffin block 
of the patients and controls. These sections were then 
dewaxed twice in dimethyl benzene for 10 min each. 
After dehydratation by ethanol gradient, the endogenous 
peroxydase was eliminated by 3% H2O2, and then tis-
sues were reduced using EDTA (pH 8.0) solution. Then 
sections went through 5 min of intensive heating, 2 min 
room temperature (RT) cooling, 20 min medium and 
low heating to allow antigens to be fully exposed. After 
natural cooling at RT, solution A from the SP kit (Beijing 
Zhongshan, China) was added to the sections and incu-
bated for 15 min at RT before the over night incubation 
with mouse anti-human Bmi-1 antibody at 4 oC. Sections 
were then flushed with 1×PBST (0.1% Tween in 1 x PBS) 
three times, 5 min each. After washing, solution B from 
the SP kit was added to the slides and incubated for 
15 min at RT before three-time washing with 1× PBST, 
5 min each. Solution C was then added and slides were 
incubated for 15 min at RT, followed by three-time flush-
ing with 1 × PBST. Later, slides were developed with 
DAB for 10 min and restained with hematoxylin before 
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fixed with ethanol hydrochloride. Finally, slides were 
mounted and observed under a light microscope. Similar 
treatment without primary antibody was adopted as the 
negative control.  
Modified TRAP-silver staining [11]. For protein 
isolation, pre-chilled lysis buffer 200 μl (10 mM Tris-HCl, 
pH7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM PMSF, 5 mM 
β-mercaptoethanol, 0.5% CHAPS, 10% glycerine) was 
added to 40–80 mg of tissues from each sample. Tis-
sues were homogenized completely in an iced bath and 
sit on ice for 30 min before centrifugation for 20 min, at 
16,000 rpm, 4 °C. Supernatants were transferred to new 
tubes and the protein concentrations were determined. 
Protein samples were aliquoted and stored at -70 °C. 
For the TRAP-PCR reaction, a 25 μl of total reaction 
was prepared, which included 20 mM Tris-HCl (pH 8.0), 
1.5 mM MgCl2, 63 mM KCl, 0.005% Tween-20, 1 mM 
EGTA, 50 μM dNTP, Forward and Reverse primers 
0.1 μg, 1 unit Taq polimerase and 0.5–1 μl telomerase 
extract (5 μg total protein). Amplification conditions 
were as the following: 25 °C for 30 min, 94 °C for 2 s, 
followed by 30 cycles of 94 °C for 30 s, 50 °C for 30 s, 
72 °C for 90 s and a final elongation step — 10 min at 
72 °C. PCR products were separated in 12% native 
polyacrylamide gel, and silver stained. Cellular extract 
of cell line 293, which had constant positive telomerase 
activity, was adopted as positive control, and cell free 
lysis buffer was used as negative control for the TRAP 
assay.
Data assessment. Expression levels of Bmi-1 
protein were visualized by observing the stained tissues 
under a light microscope. Positive expression of Bmi-1 
was defined as the presence of brown or yellowish brown 
granules in the nuclei, though occasionally yellowish 
brown granules could also be seen in the cytoplasm. 
Four fields were randomly chosen under high power lens 
(400 ×) and cell numbers with positive Bmi-1 expression 
was counted and scored according to the percentage of 
positive cells. When positive cells were less than 10%, it 
was rated as 1 point; 10% to 50%, 2 points; 50% to 75%, 
3 points and > 75%, 4 points. Meanwhile, the staining 
degree was also scored: negative, 1 point; weak staining, 
2 points; medium staining, 3 points; and strong stain-
ing, 4 points. The two different scores of corresponding 
sample were then multiplied. Points equal or less than 4 
was marked as (−); 4 points to 8 points was marked as 
(+); 8 points to 12 points, (++); and 12 points  to 16 points, 
(+++). For statistical analysis, (−) and (+) were counted 
as negative and weak positive respectively, while (++) 
and (+++) were counted as strong positive. Results were 
observed and assessed by at least two pathologic doc-
tors, without knowing the identity of the samples. 
Statistical analysis. Statistical analysis was con-
ducted with SPSS 13.0 (SPSS Inc., Chicago, IL, USA). 
Data were analyzed with χ2 test and probabilities in four-
fold table. Correlation analysis was performed for exact 
probability and enumeration (Spearman correlation 
analysis). P < 0.05 was set as the significance level.
RESULTS
Expression of Bmi-1 protein in ovarian epithe-
lial cancer tissues. Immunohistochemical examina-
tion of the 47 ovarian epithelial cancer specimens 
revealed that the positive expression rate of Bmi-1 was 
80.85% (38/47) and positive expression was mainly 
concentrated in the nuclei of tumor cells (Fig. 1). 
Strong positive rate of Bmi-1 expression was 46.81% 
(22/47).
a
b
Fig. 1. Expression of Bmi-1 protein in tissues of ovarian epithelial 
cancer. a: A typical histochemical staining of the tissue with posi-
tive expression of Bmi-1. The yellowish brown to brown granules 
in the nuclei represent the location of Bmi-1 protein; b: A sample 
with negative expression of Bmi-1. (400 ×)
As summarized in Table 1, Bmi-1 expression of grade 
G3 was higher than that of grade G2, and the difference 
was significant (χ2 = 7.3423, χ2 0.01, 1 = 6.63, P < 0.01). Ex-
pression rate for clinical stage phase II and III was 66.67%, 
92.31% for phase IV, and the difference was significant 
(χ2 = 4.46, χ2 0.05, 1 = 3.84, P < 0.05). No significant differ-
ence in Bmi-1 expression was found between serous and 
mucous tissues (χ2 = 0.0747, χ2 0.05, 1 = 3.84, P > 0.05).
Table 1. Expression of Bmi-1 protein in epithelial ovarian cancer of vari-
ous clinopathological types
Clinicopathological types 
of tumors Total − + ++
Posi-
tive, %
Strong 
positive, %
Pathological type:
serous ovarian cancer 28 5 10 13 82.15 46.43
mucinous ovarian cancer 19 4 6 9 78.95 47.37
Histological grades:
G2 18 7 6 5 61.11 27.78
G3 29 2 10 17 93.10 58.62
Clinical stage:
II & III 21 7 8 6 66.67 28.57
IV 26 2 8 16 92.31 61.54
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Detection of telomerase activity. A representa-
tive result of the modified TRAP-silver staining [11] of 
the specimens was shown on Fig. 2. Table 2 summa-
rized data of telomerase activity in ovarian epithelial 
cancer and normal ovarian epithelia tissues. The posi-
tive rate of telomerase activity was 87.23% (41/47) for 
ovarian epithelial cancer samples, while no expression 
was observed in normal ovarian epithelial tissues. No 
significant differences was observed between serous 
and mucous tissues (χ2 = 0.1437), G2 and G3 grades 
(χ2 = 0.0717) or phases II–III and IV (χ2 = 0.0787) speci-
mens (χ2 0.05, 1 = 3.84, P > 0.05).
M  1  2  3  4  5  6  7
40 bp
Fig. 2. Telomerase activities in tissues of ovarian epithelial 
cancer as examined by telomere repeat amplification protocol. 
Lane M, 293 cell used as positive control; Lane 1, tissue free 
sample used as negative control; Lanes 2–7, tissue samples 
from 6 selected cases
Table 2. Telomerase activity in epithelial ovarian cancer of various 
 clinopathological types
Clinicopathological types 
of tumors Total
Telomerase activity
− + Positive, %
pathological type:
serous ovarian cancer 28 4 24 85.71
mucinous ovarian cancer 19 2 17 89.47
histological grades:
G2 18 2 16 88.89
G3 29 4 25 86.21
clinical stage:
II & III 21 3 18 85.71
IV 26 3 23 88.46
Total cases 47 6 41 87.23
Correlation analysis of telomerase activity 
and Bmi-1 protein expression. Results indicated 
significant difference in Bmi-1 protein expression 
levels in tissues of the patients with positive and nega-
tive telomerase activity (χ2 = 18.3018, χ20.01, 1 = 6.63, 
P < 0.01) (Table 3). In tissues with positive telomerase 
activity, the expression rate of Bmi-1 was remarkably 
high (90.24%, 37/41). In telomerase activity negative 
specimens, the expression rate of Bmi-1 protein was 
much lower (16.67%, 1/6). Spearman correlation anal-
ysis indicated that Bmi-1 expression and telomerase 
activity were positively correlated (P < 0.05).
Table 3. Correlation of telomerase activity and Bmi-1 expression
Bmi-1 protein
+ −
Telomerase activity (+) 37/41 (90.24%) 4/41 (9.76%)
Telomerase activity (-) 1/6 (16.67%) 5/6 (83.33%)
DISCUSSION
Bmi-1 belongs to the polycomb gene family, which 
includes RAE28, Bmi-1, EZH2, etc. and controls gene 
activities during the body growth. Bmi-1 is an exten-
sively expressed neucleoprotein and it can act as a 
transcription factor providing specific undisturbed 
inhibition of targeted gene promoters, such as HOX 
[12]. Bmi-1 expression is associated with the charac-
teristics of both normal and tumor stem cells, maintain-
ing the normal size of stem cell pool [13, 14]. Recently 
published data testify that an acute small interfering 
RNA-mediated knockdown of Bmi-1, which resulted in 
apoptosis in cancer cells but not in normal cells [15]. 
Cells with overexpressed Bmi-1 have been indicated 
as the “tumor stem cell” in carcinomas [16].
More and more studies have suggested that Bmi-1 
is a proto-oncogene involved in the genesis of multiple 
carcinomas, such as B cell lymphoma, carcinomas 
of nervous system, etc. It has been demonstrated 
that Bmi-1 is a target gene for SALL4, and SALL4 is 
expressed constitutively in human leukemia cell lines 
and primary acute myeloid leukemia (AML) cells [17]. 
Bmi-1 was first proposed as an oncogene in the pas-
sage of lymphoma cells in transgenic mice [18], where 
researchers found a synergistic effect between Bmi-1 
and c-myc, and Bmi-1 induced the cellular transfor-
mation and tumor formation. Recent data had shown 
that Bmi-1 was a c-Myc target and its’ promoter region 
contained a functional E-box, by which c-myc and 
Mel-18 regulate expression of Bmi-1 during cellular 
senescence in human cells [19]. Bmi-1 was reported 
to induce the immortalization of breast epithelial cells 
[20], and was found to be overexpressed in naso-
pharyngeal carcinoma [21]. Bmi-1 gene alone could 
successfully induce the immortalization of nasopha-
ryngeal epithelial cells, and its expression correlated 
with the infiltration range, survival and prognosis of 
nasopharyngeal carcinoma [21]. This data provides 
powerful evidences that Bmi-1 is an oncoprotein.
In this study, Bmi-1 was found to be upregulated in 
serous and mucous ovarian cancers, and the expression 
rate had nothing to do with pathological types, but related 
to histological grades and clinical phases. Expression 
rate of Bmi-1 in poorly differentiated tissues was notably 
higher than well differentiated tissues, and the expres-
sion rate was higher when clinical phase became more 
advanced. These results suggested that Bmi-1 could play 
important role in ovarian cancer progression.
In recent years, numerous researches have studied 
the telomerase expression in ovarian cancers. Telomerase 
is a nuclear ribonuclear protein that elongates the end of 
telomere. Once activated, telomerase can overcome the 
shortening effect of telomere during cell cycling and im-
mortalize cells, which is necessary for malignancy. Telom-
erase activation is crucial in the genesis and development 
of tumors [9], and it generally found in ovarian cancers as 
demonstrated by Datar et al [22] and Park et al [23].
Results presented in this study indicated close and 
positive correlation of Bmi-1 expression and telomerase 
activity. Overexpression of Bmi-1 was clearly seen in tis-
sues with positive telomerase activity. These data were 
consistent with previous studies [10, 24]. Dimri et al [25] 
observed overexpression of Bmi-1 protein in immor-
talized breast epithelial cells and breast cancer cells, 
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where Bmi-1 oncogene could increase the cell replica-
tion time and lead to cell immortalization. Takeda et al 
[24] found that Bmi-1 regulates the human telomerase 
reverse transcriptase (hTERT) promoter via the c-myc 
pathway. Peptide deletion analysis of Bmi-1 protein indi-
cated that the ring finger and helix-turn-helix structures 
were necessary to induce telomerase activation and 
immortalization of epithelial cells. Overexpression of 
Bmi-1 in breast epithelial cells was suggested to activate 
the hTERT transcription and further induce telomerase 
activation [26]. In another study, overexpression of 
Bmi-1 was found to prolong multiplication period and 
block apoptosis of the cells through inhibition of p16INK4a 
expression [27]. Based upon literature data and our 
results, we can speculate that Bmi-1 overexpression in 
tissues with positive telomerase could correlate with the 
following events: after activation, the oncoprotein Bmi-1 
participates in cellular multiplicative division and causes 
the downregulation of p16INK4a, which prolonges the life 
period of ovarian epithelial cancer cells, promotes the 
proliferation and decreases apoptosis rate. Meanwhile, 
Bmi-1 could have activated hTERT transcription and 
induced telomerase activation, therefore immortalized 
the relevant cells.
Our results also suggested the positive correlation 
between the Bmi-1 expression level and the telomerase 
activity in ovarian epithelial cancer tissues. Bmi-1 is pre-
sumed to play important roles in ovarian epithelial cancer 
progression and regulate telomerase activation. It is likely 
that blocking of Bmi-1 expression could decrease the 
telomerase activity, hence providing a new study direction 
for genetic treatment against ovarian cancer. Therefore, 
further studies are needed to clarify the mechanisms of 
Bmi-1 regulation of telomerase activation.
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КОРРЕЛЯЦИЯ ЭКСПРЕССИИ БЕЛКА BMI-1 И АКТИВНОСТИ 
ТЕЛОМЕРАЗЫ В ТКАНЯХ РАКА ЯИЧНИКА
Цель: изучить корреляцию между экспрессией протеина Bmi-1 и активностью теломеразы при раке яичника. Методы: по-
добраны оптимальные условия для SP-иммуногистохимии для выявления экспрессии белка Bmi-1 при эпителиальном раке 
яичника (n = 47). Для определения активности теломеразы был использован усовершенствованый протокол амплификации 
теломерных повторов (TRAP, методика окрашивания серебром). Результаты: в 80,85% (38/47) случаев рака яичника была 
выявлена экспрессия белка Bmi-1, в 46,81% (22/47) случаев – на очень высоком уровне. Уровень экспрессии Bmi-1 зависел от 
степени дифференцировки опухоли (при G3 экспрессия Bmi-1 (93,10%) была выше, чем при G2 (61,11%)) и от стадии заболе-
вания (уровень экпрессии ниже в стадиях II и III (66,67%), чем в стадии IV (92,31%)). В тканях эпителиального рака яичника 
в 87,23% (41/47) случаев выявлена положительная теломеразная активность, в отличие от нулевой активности в нормальных 
тканях. В большинстве исследованных случаев рака яичника (90,24%) при положительной активности теломеразы был отмечен 
высокий уровень экспрессии Bmi-1. Корреляционный анализ Спирмана показал, что экспрессия белка Bmi-1 положительно 
коррелирует с повышенной теломеразной активностью. Выводы: белок Bmi-1 экспрессирован на высоком уровне злокачествен-
ными клетками эпителиального рака яичника, и экспрессия этого белка коррелирует с гистологической градацией и клинической 
стадией рака. Увеличение экспрессии Bmi-1 коррелировало с повышенной теломеразной активностью. 
Ключевые слова: экспрессия Bmi-1, теломеразная активность, рак яичника.
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